Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Board hears Aon briefing on GLP‑1 costs, biosimilars and PBM risks
Summary
Aon presented pharmacy benefit trends to the Health Service Board, highlighting rapid growth in GLP‑1 medications that is driving plan costs, potential near-term savings from biosimilars for biologics, and ongoing scrutiny of large PBMs by federal regulators.
The San Francisco Health Service Board heard an extensive briefing from Aon on pharmacy benefit trends, including clinical changes, cost drivers, PBM market structure and pending legislation.
Kelvin Richards, a pharmacist and Aon vice president, told the board that GLP‑1 medications—used for diabetes and increasingly for weight loss—have driven substantial recent spending increases. "Diabetes and obesity impact more than 50 percent of individuals in The United States and we expect these drugs to…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
